Anastrozole 1 mg Teva | SOU-0005

Use of Anastrozole 1 mg Teva in British Sport and Medicine.

First-line therapy for locally advanced breast cancer with unknown or hormone receptor-positive tumours in the post-menopause. Adjuvant therapy for early breast cancer with positive hormone receptors in the postmenopause. Therapy for advanced breast cancer after treatment with tamoxifen (second-line). 

The anticancer drug Anastrozole-Teva is prescribed for patients being treated for breast cancer. It is also used after tamoxifen adjuvant therapy for 2-3 years. The drug is active in the treatment of oestrogen-dependent breast tumours. The growth of this type of tumour in postmenopausal women is affected by estradiol. It can also be used to treat elderly people, the dosage is maintained for them. The drug is very effective, so I often prescribe it to my patients. As adjuvant treatment, Anastrozol-Teva should be continued for 5 years, with periodic dose adjustments and monitoring of the woman.

To reduce the risk of adverse reactions, it is recommended to take the drug without interruption, at the same time. During treatment, women should not drive, as their speed of reaction is reduced. Some patients experience drowsiness and asthenia while taking Anastrozole-Teva, which disappear after stopping the drug.

Dosage and administration Anastrozole 1 mg Teva 

Adults, including elderly patients, take orally (orally with water) 1 mg once daily for an equal amount of time. If there are signs of disease progression, it is recommended to stop taking the drug. You can always buy Anastrozole 1 mg Teva in UK on our website.

Drug interaction Anastrozole

No relevant drug interactions have been identified when taking Anastrozole concomitantly with other commonly prescribed drugs, in particular, no information is available on its use in combination with other anticancer drugs. Drugs containing oestrogens reduce the pharmacological effect of anastrozole and therefore should not be prescribed concomitantly with anastrozole. Tamoxifen should not be used concomitantly with anastrozole due to its reduced pharmacological effect.

Special bites Anastrozole Teva 

Uterine bleeding may occur with anastrozole. A gynaecologist should be consulted and monitored if this is the case. It is also necessary to confirm the hormonal status of the patient. Menopause is determined by the concentration of sex hormones in the blood serum.

In osteoporosis, bone mineral density is assessed at the start and regularly during treatment with densitometry, such as DEXA scans (dual-energy X-ray absorptiometry). Therapeutic and prophylactic procedures should be carried out as necessary and the patient's condition should be closely monitored. As Anastrozole-Teva decreases circulating estradiol concentrations, this may lead to a decrease in bone mineral density. There are no data on concomitant use of anastrozole and GnRH analogues. No efficacy of anastrozole has been observed in women with estrogen receptor negative tumours unless there is previous positive clinical experience with tamoxifen. Estrogen-containing medications should not be administered concomitantly with Anastrozole-Teva as they have a negative effect on its pharmacological effects.